ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Antiviral drugs >Lopinavir

Lopinavir

Lopinavir Suppliers list
Company Name: BOC Sciences
Tel: 1-631-619-7922
Email: inquiry@bocsci.com
Products Intro: Product Name:Lopinavir
CAS:192725-17-0
Purity:>=98% Package:1g;198USD
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718
Email: sales@capotchem.com
Products Intro: Product Name:Lopinavir
CAS:192725-17-0
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Lopinavir
CAS:192725-17-0
Purity:99% Package:100g,500g,1KG,10KG,100KG
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:lopinavir
CAS:192725-17-0
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:192725-17-0
Purity:99% Package:500G;1KG;5KG;25KG

Lastest Price from Lopinavir manufacturers

  • Lopinavir
  • US $198.00 / g
  • 2020-05-14
  • CAS:192725-17-0
  • Min. Order: 1g
  • Purity: ≥98%
  • Supply Ability: 10kg
  • Lopinavir
  • US $0.01-1.00 / KG
  • 2020-05-03
  • CAS:192725-17-0
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 50 tons
  • Lopinavir
  • US $1.00 / KG
  • 2019-07-06
  • CAS:192725-17-0
  • Min. Order: 1G
  • Purity: 98%
  • Supply Ability: 100KG
Lopinavir Basic information
Product Name:Lopinavir
Synonyms:LOPINAVIR;(2s)-n-[(2r,4s,5s)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenyl-hexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide;(aS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-a-(1-methylethyl)-2-oxo-1(2H)-Pyrimidineacetamide;A 157378.0;ABT 378;Aluviran;Koletr;134368
CAS:192725-17-0
MF:C37H48N4O5
MW:628.8
EINECS:
Product Categories:Pharmaceutical;Other APIs;Chiral Reagents;Anti-viral Compounds;Anti-virals;Intermediates & Fine Chemicals;Non-nucleoside Reverse Transcriptase;Pharmaceuticals;Pepetides;ProteaseInhibitors;API;peptides;ABT-378
Mol File:192725-17-0.mol
Lopinavir Structure
Lopinavir Chemical Properties
Melting point 124-127°C
Boiling point 924.1±65.0 °C(Predicted)
density 1.163±0.06 g/cm3(Predicted)
storage temp. Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility DMSO: soluble20mg/mL, clear
form powder
pka13.89±0.46(Predicted)
color white to beige
optical activity[α]/D -20 to -27°, c = 0.4 in methanol
Stability:Hygroscopic
CAS DataBase Reference192725-17-0(CAS DataBase Reference)
Safety Information
RIDADR 3077
HS Code 29335990
MSDS Information
Lopinavir Usage And Synthesis
DescriptionLopinavir, the sixth HIV protease inhibitor in the “navir” class, was launched in coformulation with ritonavir, another HIV protease inhibitor already marketed (Abbott, 1996); this original formulation was introduced as Kaletra for use in combination with either nucleoside or non-nucleoside reverse transcriptase inhibitors for the treatment of AIDS in adults and children. Lopinavir is a peptidomimetic compound with a structural core identical to that of ritonavir, on which terminal groups, particularly a modified valine, were introduced by peptide coupling procedures. Lopinavir is a potent competitive inhibitor of HIV-I protease exhibiting high potential against ritonavir-resistant mutations. In several animal species, pharmacokinetic studies with the lopinavirlritonavir association showed that the modest properties of lopinavir were significantly improved in presence of ritonavir, in terms of Cmax and duration of action. Ritonavir inhibits the P450 isoenzyme CYP3A4 and the human liver microsomal metabolism of lopinavir, so strongly amplifying plasma levels of this latter component. In AIDS patients, the plasma HIV RNA level was considerably reduced and the CD4+ T-cell counts increased after administration of lopinavir combined with relatively small doses of ritonavir. Kaletra is intended to be used jointly with other antiretroviral agents.
Chemical PropertiesWhite Crystalline Solid
OriginatorAbbott (US)
UsesA selective HIV protease inhibitor. An analogue of Ritonavir. Antiviral.
UsesLopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM
DefinitionChEBI: A dicarboxylic acid amide in which a parent structure of amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3- ethyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.
IndicationsLopinavir is available in the United States only as a fixed-dose combination with ritonavir (Kaletra). In this regimen, a low dose of ritonavir is used to inhibit the rapid inactivation of lopinavir by CYP3A4.
Manufacturing ProcessManufacturing process for Lopinavir includes these steps as follows: Synthesis of 2,6-dimethylphenoxyacetic acid; 2,6- dimethylphenoxyacetyl chloride as an oil; synthesis of (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(tbutyloxycarbonylamino)-1,6-diphenylhexane; (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5- amino-1,6-diphenylhexane as a white needles; synthesis of N-carbonylbenzyloxy-3- aminopropanol;synthesis of N-carbonylbenzyloxy-3-aminopropanal solution; N-(N- (benzyloxycarbonyl-3-amino)-propyl)valine methyl ester, oil state; synthesis of 2S-(1-tetrahydro-pyrimid-2-onyl)-3- methyl butanoic acid methyl ester;synthesis of 2S-(1- tetrahydro-pyrimid-2-onyl)-3-methyl butanoic acid methyl ester. The mixture of (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5- amino-1,6-diphenylhexane (100 g, 0.22 mol), 2S-(1-tetrahydro-pyrimid-2- onyl)-3-methyl butanoic acid methyl ester (44.8 g, 0.22 mol) and 750 ml DMF was cooled in an ice/water bath. N-Hydroxybenzotriazole (90.9 g, 0.67 mol), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (86 g, 0.45 mol) and triethylamine (62.5 ml, 0.45 mol) were added and the ice bath was removed, allowing the reaction mixture to stir with warming to room temperature for 5 hours. The mixture was diluted with 1000 ml of IPAC and quenched with 1000 ml of water. The mixture was shaken and separated, the aq. layer was extracted IPAC, the organics were washed with 10% HCl, solution of NaHCO3 with 100 ml hexanes, then washed 500 ml water, and brine, dried over MgSO4, filtered and concentrated to provide. (2S,3S,5S)-2-(2,6- dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)- 3-methylbutanoyl)amino-1,6-diphenylhexane as a white foam.
Brand nameKaletra
Therapeutic FunctionAntiviral
Antimicrobial activityLopinavir is active against HIV-1 and HIV-2.
Acquired resistanceSignificant resistance to the antiretroviral efficacy of ritonavirbooted lopinavir occurs as a result of amino acid substitutions at positions 32, 47 and 82 in the protease region. Protease inhibitor resistance is uncommon in patients identified with early failure of combination therapy with ritonavir boostedlopinavir and nucleotide reverse transcriptase inhibitors.
General DescriptionLopinavir is a protease inhibitor that has been approved foruse in combination with ritonavir for patients with HIV whohave not responded to other treatment modalities. Lopinaviris used in excess over ritonavir. Ritonavir at amounts givenhas no antiretroviral activity, Ritonavir inhibits lopinavir’smetabolism by CYP3A4, causing a higher level of lopinavirin the system. The combination is the first protease inhibitorapproved for patients as young as 6 months of age.
Pharmaceutical ApplicationsA synthetic compound, co-formulated with ritonavir for oral administration. In this formulation, ritonavir functions to inhibit the metabolic clearance of lopinavir, and does not contribute to the antiretroviral activity.
PharmacokineticsOral absorption: Not known/available
Cmax 400 mg + ritonavir 100 mg twice daily: c. 9.6 mg/L
Cmin 400 mg + ritonavir 100 mg twice daily: c. 5.5 mg/L
Plasma half-life: c. 5–6 h
Volume of distribution: Not known/available
Plasma protein binding: c. 98–99%
Absorption and distribution
The absorption of lopinavir–ritonavir in capsule or liquid form is favorably affected by the presence of food, particularly if high in fat. The CNS penetration is good. It has a semen:plasma ratio of 0.07. It is distributed into breast milk.
Metabolism
Lopinavir is extensively metabolized by the CYP3A4 system, but this is inhibited by ritonavir.
Excretion
Over an 8-day period after single dosing with the combined formulation, around 10% and 83% of the administered dose is recovered in urine and feces, respectively. Less than 3% of the dose is recovered as unchanged drug in urine and 20% in feces. In mild to moderate hepatic impairment, an increase in exposure of approximately 30% is observed, but is probably not clinically relevant. It should be avoided in severe hepatic impairment.
Clinical UseTreatment of HIV infection (in combination with ritonavir and other antiretroviral agents)
Side effectsThe most common adverse events seen in trials of complex antiretroviral regimens were diarrhea, nausea, headache, fatigue, vomiting and rash. Ritonavir-boosted lopinavir is associated with a dyslipidemia profile characteristic of those treated with other protease inhibitors boosted with 200 mg of ritonavir.
Side effectsSide effects, which are generally mild, include diarrhea, nausea, asthenia, and headache. Pancreatitis occurs rarely. Ritonavir is a potent inhibitor of CYP3A4 and also inhibits CYP2D6. In addition to the drugs contraindicated for all protease inhibitors, flecainide, propafenone, pimozide, and rifampin should not be given with lopinavir–ritonavir combination therapy.
Tag:Lopinavir(192725-17-0) Related Product Information
LOPINAVIR, [3H]- LOPINAVIR-D8 Lopinavir Diphenyldiethoxysilane Diphenyldimethoxysilane AMINO ACIDS Sodium triacetoxyborohydride Glycine 6-Aminocaproic acid Acetyl-resveratrol Diphenylsilanediol Acetylacetone Acetoxyacetyl chloride CHLOROPHOSPHONAZO III ALTRENOGEST Acetoxyacetic acid Tris Base Dimethyldimethoxysilane